FDA approves Sunovion’s Latuda to treat some cases of bipolar disorder

Sunovion Pharmaceuticals Inc., a Marlborough drug company owned by Dainippon Sumitomo Pharma Co., of Japan, has received regulatory approval to market its Latuda drug for additional uses in the United States.

Latuda was initially approved by the Food and Drug Administration as a treatment for adults with schizophrenia in 2010. Now the FDA has approved it as a treatment for adults with major depressive episodes associated with bipolar disorder, Sunovion said Wednesday.


The FDA approval allows Latuda to be prescribed as a single drug or as part of a drug cocktail with either Lithium or Valproate.

According to Sunovion, there are few treatments approved for bipolar depression. As a result, the FDA’s approval of Latuda for this condition is a significant event for both patients and the health care providers.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

The FDA’s approval for Latuda to treat bipolar disorder requires additional language in the so-called black box warning on the drug’s label for schizophrenia. The black box warning is the agency’s most serious caution. All other medications used for the treatment of bipolar disorder include similar warnings, Sunovion noted.

Sunovion was previously known as Sepracor Inc.

Chris Reidy

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of